Pharmacokinetics effects of chuanxiong rhizoma on warfarin in pseudo germ-free rats

In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still being determined. The present study explored the pharmacokinetics interactions of warfarin, Chuanxiong Rhizoma, and gut microbiota in the rat mod...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 1022567
Main Authors Li, Haigang, Zhou, Yi, Liao, Luanfeng, Tan, Hongyi, Li, Yejun, Li, Zibo, Zhou, Bilan, Bao, Meihua, He, Binsheng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.01.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still being determined. The present study explored the pharmacokinetics interactions of warfarin, Chuanxiong Rhizoma, and gut microbiota in the rat model of middle cerebral artery occlusion (MCAO). A total of 48 rats were randomly divided into six groups: MCAO rats orally administered warfarin (W group), pseudo germ-free MCAO rats orally administered warfarin (W-f group), MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W group), pseudo germ-free MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W-f group), MCAO rats co-administered warfarin and senkyunolide I (S + W group); pseudo germ-free MCAO rats co-administered warfarin and senkyunolide I (S + W-f group). After treatment, all animals' blood and stool samples were collected at different time points. The stool samples were used for 16S rRNA sequencing analysis. Ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method was established to quantify warfarin, internal standards, and the main bioactive components of Chuanxiong in blood samples. The main pharmacokinetics parameters of warfarin were calculated by DAS 2.1.1 software. The relative abundance of and in the pseudo germ-free groups (W-f, C + W-f, S + W-f) was lower than that in the other three groups (W, C + W, S + W). The relative abundance of in the W-f group was higher than that of the W group, while the relative abundance of decreased. The relative abundance of Ruminococcaceae and Ruminococcaceae in the S + W-f group was lower than in the S + W group. Compared to the W group, the AUC and C of warfarin in the W-f group increased significantly to 51.26% and 34.58%, respectively. The AUC and C in the C + W group promoted 71.20% and 65.75% more than the W group. Compared to the W group, the AUC and C increased to 64.98% and 64.39% in the S + W group. Chuanxiong Rhizoma and senkyunolide I (the most abundant metabolites of Chuanxiong Rhizoma aqueous extract) might affect the pharmacokinetics features of warfarin in MCAO rats through, at least partly, gut microbiota.
AbstractList Aim: In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still being determined. The present study explored the pharmacokinetics interactions of warfarin, Chuanxiong Rhizoma, and gut microbiota in the rat model of middle cerebral artery occlusion (MCAO).Methods: A total of 48 rats were randomly divided into six groups: MCAO rats orally administered warfarin (W group), pseudo germ-free MCAO rats orally administered warfarin (W-f group), MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W group), pseudo germ-free MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W-f group), MCAO rats co-administered warfarin and senkyunolide I (S + W group); pseudo germ-free MCAO rats co-administered warfarin and senkyunolide I (S + W-f group). After treatment, all animals’ blood and stool samples were collected at different time points. The stool samples were used for 16S rRNA sequencing analysis. Ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method was established to quantify warfarin, internal standards, and the main bioactive components of Chuanxiong in blood samples. The main pharmacokinetics parameters of warfarin were calculated by DAS 2.1.1 software.Results: The relative abundance of Allobaculum and Dubosiella in the pseudo germ-free groups (W-f, C + W-f, S + W-f) was lower than that in the other three groups (W, C + W, S + W). The relative abundance of Lactobacillus in the W-f group was higher than that of the W group, while the relative abundance of Akkermansia decreased. The relative abundance of Ruminococcaceae_UCG-014 and Ruminococcaceae_NK4A214_group in the S + W-f group was lower than in the S + W group. Compared to the W group, the AUC0-t and Cmax of warfarin in the W-f group increased significantly to 51.26% and 34.58%, respectively. The AUC0-t and Cmax in the C + W group promoted 71.20% and 65.75% more than the W group. Compared to the W group, the AUC0-t and Cmax increased to 64.98% and 64.39% in the S + W group.Conclusion: Chuanxiong Rhizoma and senkyunolide I (the most abundant metabolites of Chuanxiong Rhizoma aqueous extract) might affect the pharmacokinetics features of warfarin in MCAO rats through, at least partly, gut microbiota.
Aim: In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still being determined. The present study explored the pharmacokinetics interactions of warfarin, Chuanxiong Rhizoma, and gut microbiota in the rat model of middle cerebral artery occlusion (MCAO). Methods: A total of 48 rats were randomly divided into six groups: MCAO rats orally administered warfarin (W group), pseudo germ-free MCAO rats orally administered warfarin (W-f group), MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W group), pseudo germ-free MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W-f group), MCAO rats co-administered warfarin and senkyunolide I (S + W group); pseudo germ-free MCAO rats co-administered warfarin and senkyunolide I (S + W-f group). After treatment, all animals’ blood and stool samples were collected at different time points. The stool samples were used for 16S rRNA sequencing analysis. Ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method was established to quantify warfarin, internal standards, and the main bioactive components of Chuanxiong in blood samples. The main pharmacokinetics parameters of warfarin were calculated by DAS 2.1.1 software. Results: The relative abundance of Allobaculum and Dubosiella in the pseudo germ-free groups (W-f, C + W-f, S + W-f) was lower than that in the other three groups (W, C + W, S + W). The relative abundance of Lactobacillus in the W-f group was higher than that of the W group, while the relative abundance of Akkermansia decreased. The relative abundance of Ruminococcaceae _UCG-014 and Ruminococcaceae _NK4A214_group in the S + W-f group was lower than in the S + W group. Compared to the W group, the AUC 0-t and C max of warfarin in the W-f group increased significantly to 51.26% and 34.58%, respectively. The AUC 0-t and C max in the C + W group promoted 71.20% and 65.75% more than the W group. Compared to the W group, the AUC 0-t and C max increased to 64.98% and 64.39% in the S + W group. Conclusion: Chuanxiong Rhizoma and senkyunolide I (the most abundant metabolites of Chuanxiong Rhizoma aqueous extract) might affect the pharmacokinetics features of warfarin in MCAO rats through, at least partly, gut microbiota.
In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still being determined. The present study explored the pharmacokinetics interactions of warfarin, Chuanxiong Rhizoma, and gut microbiota in the rat model of middle cerebral artery occlusion (MCAO). A total of 48 rats were randomly divided into six groups: MCAO rats orally administered warfarin (W group), pseudo germ-free MCAO rats orally administered warfarin (W-f group), MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W group), pseudo germ-free MCAO rats co-administered Chuanxiong Rhizoma and warfarin (C + W-f group), MCAO rats co-administered warfarin and senkyunolide I (S + W group); pseudo germ-free MCAO rats co-administered warfarin and senkyunolide I (S + W-f group). After treatment, all animals' blood and stool samples were collected at different time points. The stool samples were used for 16S rRNA sequencing analysis. Ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method was established to quantify warfarin, internal standards, and the main bioactive components of Chuanxiong in blood samples. The main pharmacokinetics parameters of warfarin were calculated by DAS 2.1.1 software. The relative abundance of and in the pseudo germ-free groups (W-f, C + W-f, S + W-f) was lower than that in the other three groups (W, C + W, S + W). The relative abundance of in the W-f group was higher than that of the W group, while the relative abundance of decreased. The relative abundance of Ruminococcaceae and Ruminococcaceae in the S + W-f group was lower than in the S + W group. Compared to the W group, the AUC and C of warfarin in the W-f group increased significantly to 51.26% and 34.58%, respectively. The AUC and C in the C + W group promoted 71.20% and 65.75% more than the W group. Compared to the W group, the AUC and C increased to 64.98% and 64.39% in the S + W group. Chuanxiong Rhizoma and senkyunolide I (the most abundant metabolites of Chuanxiong Rhizoma aqueous extract) might affect the pharmacokinetics features of warfarin in MCAO rats through, at least partly, gut microbiota.
Author Bao, Meihua
Li, Zibo
He, Binsheng
Li, Haigang
Zhou, Yi
Li, Yejun
Zhou, Bilan
Tan, Hongyi
Liao, Luanfeng
AuthorAffiliation 2 Department of Pharmacy , Changsha Medical University , Changsha , China
6 Department of Pharmacy , Changsha Health Vocational College , Changsha , China
4 Center of Clinical Pharmacology , The Third Xiangya Hospital , Central South University , Changsha , China
1 Hunan key laboratory of the research and development of novel pharmaceutical preparations , Changsha Medical University , Changsha , China
3 Academician Workstation , Changsha Medical University , Changsha , China
5 Department of medical laboratory , Changsha Medical University , Changsha , China
AuthorAffiliation_xml – name: 2 Department of Pharmacy , Changsha Medical University , Changsha , China
– name: 1 Hunan key laboratory of the research and development of novel pharmaceutical preparations , Changsha Medical University , Changsha , China
– name: 3 Academician Workstation , Changsha Medical University , Changsha , China
– name: 6 Department of Pharmacy , Changsha Health Vocational College , Changsha , China
– name: 5 Department of medical laboratory , Changsha Medical University , Changsha , China
– name: 4 Center of Clinical Pharmacology , The Third Xiangya Hospital , Central South University , Changsha , China
Author_xml – sequence: 1
  givenname: Haigang
  surname: Li
  fullname: Li, Haigang
  organization: Academician Workstation, Changsha Medical University, Changsha, China
– sequence: 2
  givenname: Yi
  surname: Zhou
  fullname: Zhou, Yi
  organization: Academician Workstation, Changsha Medical University, Changsha, China
– sequence: 3
  givenname: Luanfeng
  surname: Liao
  fullname: Liao, Luanfeng
  organization: Department of Pharmacy, Changsha Medical University, Changsha, China
– sequence: 4
  givenname: Hongyi
  surname: Tan
  fullname: Tan, Hongyi
  organization: Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
– sequence: 5
  givenname: Yejun
  surname: Li
  fullname: Li, Yejun
  organization: Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
– sequence: 6
  givenname: Zibo
  surname: Li
  fullname: Li, Zibo
  organization: Department of medical laboratory, Changsha Medical University, Changsha, China
– sequence: 7
  givenname: Bilan
  surname: Zhou
  fullname: Zhou, Bilan
  organization: Department of Pharmacy, Changsha Health Vocational College, Changsha, China
– sequence: 8
  givenname: Meihua
  surname: Bao
  fullname: Bao, Meihua
  organization: Academician Workstation, Changsha Medical University, Changsha, China
– sequence: 9
  givenname: Binsheng
  surname: He
  fullname: He, Binsheng
  organization: Academician Workstation, Changsha Medical University, Changsha, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36686675$$D View this record in MEDLINE/PubMed
BookMark eNpVkdtu1DAQhi1URA_0BbhAueQmS3yIDzdIqKK0UiWQgGvLtWd2UxJ7sZNSeHrc7lK11sge2f989vg_JgcxRSDkDe1WnGvzHrcbl1esY2xF69RL9YIcUSl5azRlB0_yQ3Jayk1XBzeGS_GKHHIptZSqPyLfvlbM5Hz6OUSYB18aQAQ_lyZh4zeLi3dDiusmb4a_aXJNis1vl9HlITY1tgWWkJo15KnFDNBkN5fX5CW6scDpfj0hP84_fT-7aK--fL48-3jVekHN3AoplGDGA3KHugMZnJechWvqgul76qkIiMowir6j2Ksql1x7DNgZ4ZCfkMsdNyR3Y7d5mFz-Y5Mb7MNGymvrcu1pBBtEh51UXnAKojZoKNUqSOh7hdBzXlkfdqztcj1B8BDn7MZn0OcncdjYdbq1Rov6qawC3u0BOf1aoMx2GoqHcXQR0lIsU1JryrmSVcp2Up9TKRnw8Rra2Xtz7YO59t5cuze3Fr19-sDHkv9W8n8c56SZ
Cites_doi 10.1016/j.ejmech.2019.111921
10.1523/JNEUROSCI.1114-16.2016
10.2147/DDDT.S107917
10.36290/vnl.2017.175
10.1039/d1fo01422f
10.1016/j.jpba.2004.09.054
10.11622/smedj.2018051
10.1007/s12975-017-0554-2
10.1080/03602532.2018.1497647
10.3389/fphar.2020.590453
10.1186/s12906-015-0605-8
10.2165/00003088-200241100-00005
10.3389/fphar.2018.01461
10.3389/fphar.2021.621339
10.1016/j.phrs.2020.104979
10.1007/s12035-020-02016-y
10.1002/pds.1446
10.1016/j.jep.2016.08.005
10.1016/j.thromres.2017.11.001
10.1016/S0140-6736(16)30514-1
10.7501/j/issn.0253-2670.2015.16.018
10.3168/jds.2008-1698
10.1016/j.jff.2018.05.043
10.1016/j.ctim.2017.03.006
10.1097/MD.0000000000002986
10.2165/00002018-200326080-00004
10.1016/j.jnutbio.2018.12.004
ContentType Journal Article
Copyright Copyright © 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He.
Copyright © 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He. 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He
Copyright_xml – notice: Copyright © 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He.
– notice: Copyright © 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He. 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fphar.2022.1022567
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Li et al
EISSN 1663-9812
EndPage 1022567
ExternalDocumentID oai_doaj_org_article_d40f067c431e4ffe91187d6e557fe533
10_3389_fphar_2022_1022567
36686675
Genre Journal Article
GrantInformation_xml – fundername: ;
  grantid: 18A497 18A499 20C0198
– fundername: ;
  grantid: C20180165
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
ITC
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
RIG
RNS
RPM
AAYXX
CITATION
PGMZT
7X8
5PM
ID FETCH-LOGICAL-c419t-4647429cef3af80e6dac632db1ad9551c14dff7921fc01f57474638cfdf094af3
IEDL.DBID RPM
ISSN 1663-9812
IngestDate Thu Jul 04 21:11:35 EDT 2024
Tue Sep 17 21:30:37 EDT 2024
Fri Aug 16 21:10:11 EDT 2024
Fri Aug 23 00:52:03 EDT 2024
Thu May 23 23:34:20 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords pharmacokinetics
chuanxiong
UPLC-MS/MS
gut microbiota
MCAO (middle cerebral artery occlusion)
warfarin
Language English
License Copyright © 2023 Li, Zhou, Liao, Tan, Li, Li, Zhou, Bao and He.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c419t-4647429cef3af80e6dac632db1ad9551c14dff7921fc01f57474638cfdf094af3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Chen-Hsi Hsieh, Far Eastern Memorial Hospital (FEMH), Taiwan
Liu Ju-Han, National Taipei University of Nursing and Health Sciences, Taiwan
Reviewed by: Yuxiang Fei, China Pharmaceutical University, China
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849362/
PMID 36686675
PQID 2768813376
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_d40f067c431e4ffe91187d6e557fe533
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9849362
proquest_miscellaneous_2768813376
crossref_primary_10_3389_fphar_2022_1022567
pubmed_primary_36686675
PublicationCentury 2000
PublicationDate 2023-01-05
PublicationDateYYYYMMDD 2023-01-05
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-05
  day: 05
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Cui (B6) 2015; 15
Michalcova (B15) 2018; 63
Wang (B22); 11
Li (B12) 2018; 9
Zhang (B27) 2018; 50
Zhang (B26) 2016; 95
Chen (B3) 2019; 65
Roberts (B17) 2002; 41
Miyauchi (B16) 2009; 92
(B5) 2020
McBride (B14) 2017; 8
Wang (B20) 2017; 32
Lim (B13) 2018; 59
Li (B11); 193
Chen (B4) 2020; 57
Wan (B19) 2021; 12
Awolade (B1) 2020; 187
Feng (B8) 2015; 46
Wong (B24) 2003; 26
Wilbur (B23) 2017; 95
Cuzzolin (B7) 2007; 16
Yan (B25) 2005; 37
Gu (B9) 2021; 12
Singh (B18) 2016; 36
Wang (B21); 159
Chai-Adisaksopha (B2) 2017; 160
Chen (B28) 2018; 47
Li (B10); 10
References_xml – volume: 187
  start-page: 111921
  year: 2020
  ident: B1
  article-title: Therapeutic significance of β-glucuronidase activity and its inhibitors: A review
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2019.111921
  contributor:
    fullname: Awolade
– volume: 36
  start-page: 7428
  year: 2016
  ident: B18
  article-title: Microbiota dysbiosis controls the neuroinflammatory response after stroke
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.1114-16.2016
  contributor:
    fullname: Singh
– volume: 10
  start-page: 2173
  ident: B10
  article-title: The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage
  publication-title: Drug Des. devel. Ther.
  doi: 10.2147/DDDT.S107917
  contributor:
    fullname: Li
– volume: 63
  start-page: 957
  year: 2018
  ident: B15
  article-title: The current role of warfarin
  publication-title: Vnitr Lek.
  doi: 10.36290/vnl.2017.175
  contributor:
    fullname: Michalcova
– volume: 12
  start-page: 11420
  year: 2021
  ident: B19
  article-title: Dihydroquercetin supplement alleviates colonic inflammation potentially through improved gut microbiota community in mice
  publication-title: Food Funct.
  doi: 10.1039/d1fo01422f
  contributor:
    fullname: Wan
– volume: 37
  start-page: 87
  year: 2005
  ident: B25
  article-title: Simultaneous quantification of 12 bioactive components of Ligusticum chuanxiong Hort. by high-performance liquid chromatography
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2004.09.054
  contributor:
    fullname: Yan
– volume: 59
  start-page: 230
  year: 2018
  ident: B13
  article-title: Traditional Chinese medicine: Herb-drug interactions with aspirin
  publication-title: Singap. Med. J.
  doi: 10.11622/smedj.2018051
  contributor:
    fullname: Lim
– volume: 8
  start-page: 397
  year: 2017
  ident: B14
  article-title: Precision stroke animal models: The permanent MCAO model should be the primary model, not transient MCAO
  publication-title: Transl. Stroke Res.
  doi: 10.1007/s12975-017-0554-2
  contributor:
    fullname: McBride
– volume: 50
  start-page: 357
  year: 2018
  ident: B27
  article-title: Gut microbiota modulates drug pharmacokinetics
  publication-title: Drug Metab. Rev.
  doi: 10.1080/03602532.2018.1497647
  contributor:
    fullname: Zhang
– volume: 11
  start-page: 590453
  ident: B22
  article-title: Taohong Siwu decoction ameliorates ischemic stroke injury via suppressing pyroptosis
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.590453
  contributor:
    fullname: Wang
– volume: 15
  start-page: 91
  year: 2015
  ident: B6
  article-title: Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage
  publication-title: BMC Complement. Altern. Med.
  doi: 10.1186/s12906-015-0605-8
  contributor:
    fullname: Cui
– volume: 41
  start-page: 751
  year: 2002
  ident: B17
  article-title: Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/00003088-200241100-00005
  contributor:
    fullname: Roberts
– volume: 9
  start-page: 1461
  year: 2018
  ident: B12
  article-title: The effects of warfarin on the pharmacokinetics of senkyunolide I in a rat model of biliary drainage after administration of Chuanxiong
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.01461
  contributor:
    fullname: Li
– volume: 12
  start-page: 621339
  year: 2021
  ident: B9
  article-title: Ferulic acid ameliorates atherosclerotic injury by modulating gut microbiota and lipid metabolism
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.621339
  contributor:
    fullname: Gu
– volume: 159
  start-page: 104979
  ident: B21
  article-title: The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2020.104979
  contributor:
    fullname: Wang
– volume: 57
  start-page: 4305
  year: 2020
  ident: B4
  article-title: Proteomics-guided study on Buyang Huanwu decoction for its neuroprotective and neurogenic mechanisms for transient ischemic stroke: Involvements of EGFR/PI3K/Akt/Bad/14-3-3 and Jak2/Stat3/Cyclin D1 signaling cascades
  publication-title: Mol. Neurobiol.
  doi: 10.1007/s12035-020-02016-y
  contributor:
    fullname: Chen
– volume: 16
  start-page: 1014
  year: 2007
  ident: B7
  article-title: Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: A pilot study
  publication-title: Pharmacoepidemiol. Drug Saf.
  doi: 10.1002/pds.1446
  contributor:
    fullname: Cuzzolin
– volume: 193
  start-page: 117
  ident: B11
  article-title: The effects of Chuanxiong on the pharmacokinetics of warfarin in rats after biliary drainage
  publication-title: J. Ethnopharmacol.
  doi: 10.1016/j.jep.2016.08.005
  contributor:
    fullname: Li
– volume: 160
  start-page: 97
  year: 2017
  ident: B2
  article-title: Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis
  publication-title: Thromb. Res.
  doi: 10.1016/j.thromres.2017.11.001
  contributor:
    fullname: Chai-Adisaksopha
– volume: 95
  start-page: 295
  year: 2017
  ident: B23
  article-title: Deep venous thrombosis and pulmonary embolism: Current therapy
  publication-title: Am. Fam. Physician
  doi: 10.1016/S0140-6736(16)30514-1
  contributor:
    fullname: Wilbur
– volume: 46
  start-page: 2445
  year: 2015
  ident: B8
  article-title: Interaction of Shunaoxin dripping pill and warfarin sodium on anticoagulant applications
  publication-title: Chin. Tradit. Herb. Drugs
  doi: 10.7501/j/issn.0253-2670.2015.16.018
  contributor:
    fullname: Feng
– volume: 92
  start-page: 2400
  year: 2009
  ident: B16
  article-title: Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo
  publication-title: J. Dairy Sci.
  doi: 10.3168/jds.2008-1698
  contributor:
    fullname: Miyauchi
– start-page: 42
  volume-title: Chinese Pharmacopoeia 1
  year: 2020
  ident: B5
– volume: 47
  start-page: 72
  year: 2018
  ident: B28
  article-title: The combination of Puerariae Lobatae Radix and Chuanxiong Rhizoma enhanced the absorption and pharmacokinetics of puerarin by modulating the intestinal barrier and influenced gut microbiota
  publication-title: J. Funct. Foods
  doi: 10.1016/j.jff.2018.05.043
  contributor:
    fullname: Chen
– volume: 32
  start-page: 1
  year: 2017
  ident: B20
  article-title: Efficacy and safety of traditional Chinese medicine on thromboembolic events in patients with atrial fibrillation: A systematic review and meta-analysis
  publication-title: Complement. Ther. Med.
  doi: 10.1016/j.ctim.2017.03.006
  contributor:
    fullname: Wang
– volume: 95
  start-page: e2986
  year: 2016
  ident: B26
  article-title: Traditional Chinese patent medicine for acute ischemic stroke: An overview of systematic reviews based on the GRADE approach
  publication-title: Med. Baltim.
  doi: 10.1097/MD.0000000000002986
  contributor:
    fullname: Zhang
– volume: 26
  start-page: 585
  year: 2003
  ident: B24
  article-title: Use of herbal medicines by patients receiving warfarin
  publication-title: Drug Saf.
  doi: 10.2165/00002018-200326080-00004
  contributor:
    fullname: Wong
– volume: 65
  start-page: 101
  year: 2019
  ident: B3
  article-title: Puerariae Lobatae Radix with Chuanxiong Rhizoma for treatment of cerebral ischemic stroke by remodeling gut microbiota to regulate the brain-gut barriers
  publication-title: J. Nutr. Biochem.
  doi: 10.1016/j.jnutbio.2018.12.004
  contributor:
    fullname: Chen
SSID ssj0000399364
Score 2.3519807
Snippet In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still...
Aim: In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still...
Aim: In China, warfarin is usually prescribed with Chuanxiong Rhizoma for treating thromboembolism diseases. However, the reason for their combination is still...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1022567
SubjectTerms chuanxiong
gut microbiota
MCAO (middle cerebral artery occlusion)
pharmacokinetics
Pharmacology
UPLC-MS/MS
warfarin
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS9xAEF_EJ1_E1lZTW9mC3IsGTbIfyaOKIgWLoIJvy2Z3xhNpctwHrf99Zze5806EvhTykg_Isr_Zmfkls79h7KCyUhMNKFKiXToVjsy4FHWROtC-BMqXMQrPX_9UV_fix4N8WGr1FWrCOnngbuKOvThB8qiOAh0IRKhCf2yvQEqNQLlK9L6ZXCJT0QeHuKtEt0uGWFh1jKOhDfqfeR7UCijQ65VIFAX738sy3xZLLkWfyy222aeN_LQb7ge2Bs1HNrjpdKdfjvjd6zaqyREf8JtXReqXbXY7P32mnDI8wvsyDt4id8OZbf4QPI98HArwflneNvy3HSPR6IbTMZrAzLf8kZx4imMATlYz-cTuLy_uzq_SvptC6kRWTVOhBOFROcDCEgCgvHWqyH2dWV9R3uQy4RF1lWfoTjKUxDMELU6HHokCWiw-s_WmbWCXcdS5RMKSsr9aQAlWlZgrKJ0DL2opEnY4n1kz6kQzDJGNgIOJOJiAg-lxSNhZmPzFk0HwOl4gMzC9GZh_mUHCvs-hM7RAwl8P20A7m5icCFVJTFyrhO10UC5eVShVKqJMCdMrIK-MZfVO8zSMItxVKcjC8i__Y_B7bCN0sY9fduRXtj4dz-Ab5TrTej-a9V8ivP7Z
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB2VcuGC-CZAkZFQLzTQOI6THCoEiKpCKqpEV-rNcuyZXUSbLMmu6P57xkm2ZVG5IeWSxFEiv7HnvcR5A_C6tFnOMiCNWXblsXIcxoWq0thh7gtkvky98fzxV300UV_OsrMtWJc7Gjuwu1HahXpSk_b87eXP1Xse8AdBcXK-fUfzmQ3WnlIGIwLO4fktuC1VqkLEH490v5-ZQzbWavh35h-XbuSn3sb_Ju759xLKP3LS4T24O5JJ8WFA_z5sYf0Adk8GN-rVnji9_rmq2xO74uTap3r1EL6td38w0wxNxLi4QzQk3Gxp60sGbSrasCzvwoqmFr9sSyyua8HbvMOlb8SUp_aYWkTBsdQ9gsnh59NPR_FYYyF2KikXsdKKUSodUmoZFtTeOp1KXyXWl8ymXKI8UV7KhNx-QhmrD8VD1pEnFoaW0sewXTc1PgVBucyIEWZOWCks0OqCpMbCOfSqylQEb9Y9a-aDlYZhCRJwMD0OJuBgRhwi-Bg6_6plsMHuDzTt1Iyjyni1T5xuHbMgVNxFZSie7jVmWU7IRDaCV2voDA-b8C3E1tgsOyNZZhWsz3MdwZMByqtbpVoXmoVUBPkGyBvPsnmm_j7rrbnLQnGEyWf_4-Gfw51Q275_35O9gO1Fu8QdZkCL6mUf1r8B4AIHiw
  priority: 102
  providerName: Scholars Portal
Title Pharmacokinetics effects of chuanxiong rhizoma on warfarin in pseudo germ-free rats
URI https://www.ncbi.nlm.nih.gov/pubmed/36686675
https://search.proquest.com/docview/2768813376
https://pubmed.ncbi.nlm.nih.gov/PMC9849362
https://doaj.org/article/d40f067c431e4ffe91187d6e557fe533
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS9xAGB3Up76U1t7SVplC8aXGNclcH1UqUtiyUAXfhslcdsXuZMnuov77fjNJ1C19KoRAbiTM-TLfOck3ZxD6KjXlIAOqHGQXz4mBMBakrnLjuBUO-LJPxvPjn-ziivy4ptdbiA5jYVLRvqlvjsLv-VG4maXaysXcjIY6sdFkfCYFkdDxjrbRNq-qZxI9db8x5TLSDZABASZHfjHT0fqzLKNRAeR4vpGEklf_vwjm33WSzxLP-Sv0smeM-KR7stdoy4VddDDpLKcfDvHl0wiq5SE-wJMnM-qHN-jXsHkLdDKegvsKDtx4bGZrHe4BmSluY-3dXOMm4DvdelDQAcOyWLq1bfAU-u_ct85hCJjlW3R1_v3y7CLvJ1LIDSnkKieMABTSOF9paHvHrDasKm1daCuBMpmCWO-5LAtvjgtPQWIQeC-Ntx7Un_bVO7QTmuA-IOx5ST3ACMSvJk44zYQvmRPGOEtqSjL0bWhZtej8MhTojIiDSjioiIPqccjQaWz8xzOj13Xa0bRT1SOuLDn2kFMNUB1HoIlknCHdMkcp9w7Yaoa-DNApeDfiDw8dXLNeqhK0lAARzlmG3ndQPt6qYkwwUEsZ4hsgbzzL5hEIx-S_3Yffx_--8hN6EWetT19y6Ge0s2rXbg-4zareT98EYD0mYj_F9R9wZf-r
link.rule.ids 230,315,733,786,790,870,891,2115,24346,27957,27958,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4a4wFeuDPC1UhoLyztkjh28ggTU4F1qkSH9mY5vrTTaFKljWD8eo6dZFsnXkDKS26K4-845_uS4y8A73KZcpQBSYiyi4dUYRhntEhCZbjODPJl643nx8dsdEK_nKanW5D2c2F80b4qzgblj8WgPJv72srlQg37OrHhZHyQZzTHB-_wFtzG8RrzayLdP4Bd0mW0nSKDEiwf2uVcOvPPOHZWBZjl-UYa8m79f6OYNyslr6Wew_vwvW90W3FyPmjWxUD9vuHn-M939QDudWSUfGh3P4QtUz6C3UnrZn2xR6ZXk7NWe2SXTK58ri8ew7d-9RyZqjuEdMUhpLJEzRtZ_kLQZ6R2ZX0LSaqS_JS1RXFeElyWK9PoiswwNYS2NoZgLK6ewMnhp-nBKOz-0RAqGuXrkDKKKOfK2EQirIZpqVgS6yKSOkc2piKqreV5HFm1H9kU1QvFIa-stigspU2ewnZZleYZEMvj1GKEIKcsqMmMZJmNmcmUMpoWKQ3gfQ-ZWLZWHAIljANYeICFA1h0AAfw0aF6eaSz0fYbqnomum4Xmu5bTNcKWZSh2EW5-_m6ZiZNuTVIhAN428eEwGHnvqXI0lTNSsQo0zLU95wFsNPGyOWlEsYyhkIsAL4RPRtt2dyDMeGtvbsYeP7fZ76BO6Pp-EgcfT7--gLuYo8k_oVR-hK213VjXiGFWhev_YD5Axe2H-w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbpwwFL1qU6nqpu8HfbpSlU3DEMAYvGzTjtJHopGaSFE3lvFjJkoHRsygNv36XhtIZqKuIrEBjACfa-45cDkGeMdllqMMSEOUXXlIFYZxQcs0VCbXhUG-bL3x_MEh2z-mX0-yk7WpvnzRvipPR9Wv-ag6nfnaysVcRUOdWDQ52OMF5fjgjRbaRjfhFo7ZhK8Jdf8QdomX0e43GZRhPLKLmXQGoEni7Aow0-cbqcg79v-PZl6tllxLP-N78HO48K7q5GzUrsqR-nvF0_Fad3Yf7vaklHzomjyAG6Z6CNuTztX6fIccXf6ktdwh22Ry6Xd9_gh-DKtnyFhdE9IXiZDaEjVrZfUHwZ-SxpX3zSWpK_JbNhZFekVwWSxNq2syxRQR2sYYgjG5fAzH489He_thP1dDqGjMVyFlFNHmythUIryGaalYmugylpojK1Mx1dbmPImt2o1thiqG4tBXVlsUmNKmT2CrqivzDIjNk8xipCC3LKkpjGSFTZgplDKalhkN4P0Am1h0lhwCpYwDWXiQhQNZ9CAH8NEhe9HS2Wn7DXUzFX3XC013LaZthWzKUOwi7iZh18xkWW4NEuIA3g5xIXD4uW8qsjJ1uxQJyrUCdX7OAnjaxcnFqVLGCoaCLIB8I4I2rmVzD8aFt_ju4-D5tY98A7cnn8bi-5fDby_gDnZI6t8bZS9ha9W05hUyqVX52o-Zf_dMImw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+effects+of+chuanxiong+rhizoma+on+warfarin+in+pseudo+germ-free+rats&rft.jtitle=Frontiers+in+pharmacology&rft.au=Haigang+Li&rft.au=Haigang+Li&rft.au=Haigang+Li&rft.au=Yi+Zhou&rft.date=2023-01-05&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=13&rft_id=info:doi/10.3389%2Ffphar.2022.1022567&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d40f067c431e4ffe91187d6e557fe533
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon